Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03988946
Registration number
NCT03988946
Ethics application status
Date submitted
10/01/2019
Date registered
18/06/2019
Titles & IDs
Public title
Cephea Transseptal Mitral Valve System FIH
Query!
Scientific title
Cephea Mitral Valve and Transseptal Delivery System FIH
Query!
Secondary ID [1]
0
0
CP21549
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Mitral Regurgitation
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - Transcatheter Mitral Valve Replacement via Transseptal Access
Experimental: Transcatheter Mitral Valve Replacement - Replacement valve delivered through a transfemoral access and transseptal approach
Treatment: Devices: Transcatheter Mitral Valve Replacement via Transseptal Access
The Cephea Transseptal Mitral Valve System is intended for use in symptomatic patients with moderate to severe degenerative or functional mitral regurgitation, who are poor candidates for surgery and who are anatomically eligible for the treatment.
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Safety as measured by freedom from major adverse events
Query!
Assessment method [1]
0
0
Freedom from major adverse events, including:
* All-cause mortality
* Disabling stroke
* Myocardial infarction
* Renal failure requiring dialysis
* Life-threatening bleeding
* Any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention.
Query!
Timepoint [1]
0
0
30 days
Query!
Primary outcome [2]
0
0
Performance
Query!
Assessment method [2]
0
0
Reduction in mitral regurgitation to =1+
Query!
Timepoint [2]
0
0
30 days
Query!
Eligibility
Key inclusion criteria
MVARC
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
NA
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/08/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
31/12/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
St. Vincent's Hospital - Sydney
Query!
Recruitment postcode(s) [1]
0
0
- Sydney
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Cephea Valve Technologies
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To assess the safety and performance of the Cephea Transseptal Mitral Valve System for the treatment of symptomatic moderate to severe degenerative or functional mitral regurgitation, in patients who are poor candidates for surgery.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03988946
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Helen J Scotch
Query!
Address
0
0
Cephea Valve Technologies
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Undecided
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT03988946